Eli Lilly has won its first approval to sell its weight-loss drug Foundayo in Europe, allowing it to compete with rival Novo Nordisk's Wegovy pill in the U.K. It marks only the second GLP-1 weight-loss pill in the European market and comes just two months after Novo launched its Wegovy pill there. Novo has used its months-long lead in the oral weight-loss space to position Wegovy pill in the market as the most effective oral option for losing weight. Foundayo has seen a significantly slower uptake in the U.S. than the Wegovy pill. This contrasts with the Wegovy pill, which uses the same active ingredient, semaglutide, as its injectable versions.